Inhibrx Biosciences, Inc. (NASDAQ:INBX)
| Market Cap | 1.33B+16.4% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -138.18M+15.6% |
| EPS | -8.88+17.8% |
| Shares Out | 14.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | May 30, 2024 |
| Volume | 165,638 |
| Open | 92.38 |
| Previous Close | 90.61 |
| Day's Range | 89.24 - 93.48 |
| 52-Week Range | 57.30 - 155.29 |
| Beta | 4.04 |
| Analysts | Buy |
| Price Target | 285.00(+214.60%) |
| Earnings Date | Nov 13, 2026 |
About INBX
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Inhibrx Biosciences, Inc. Stock Analysis — InsiderScore
Inhibrx Biosciences, Inc. scored higher than 98% of companies evaluated by InsiderBuying, and ranked 2nd out of 95 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Inhibrx Biosciences, Inc. bought $6.35 million of stock across 20 purchases in the last 90 days, the largest of them $1.09 million.
The average purchase added about 1% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Nov 13, 2026Earnings report
$INBX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in INBX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by INBX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
INBX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New INBX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to INBX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in INBX
| VTIVanguard Morningstar Total Stock Market ETF | $41.53M |
| XBIState Street SPDR S&P Biotech ETF | $30.57M |
| IWMiShares Russell 2000 ETF | $22.62M |
| VXFVanguard Extended Market ETF | $11.05M |
| IBBiShares Biotechnology ETF | $7.70M |
| IWOiShares Russell 2000 Growth ETF | $6.61M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from INBX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.9 since Sep 9Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.